Our Nanobrite™ imaging agent has been under development for more than 12 years in the United States, first in the laboratory of Dr. Rodney Ho at the University of Washington Medical School, and then by Nova TheraNostics Inc., a privately held biotechnology in the State of Washington. The technology has recently been exclusively licensed to Hawkeye MRI AG for final clinical development and commercialization.

Hawkeye’s mission is to bring to market safe and superior imaging agents for the early detection of diseases using MRI. Because our technology has a longer dwell time in the vasculature, and because it results in dramatically enhanced organ imagery, less advanced MRI machines can also be utilized to achieve outstandingly clear images, thus increasing the technology's market size and appeal.